Chapter 11 : Treatment and Prophylaxis of Gastroenteritis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Treatment and Prophylaxis of Gastroenteritis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap11-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap11-2.gif


This chapter reviews the characteristics of the quinolones that make them useful for the treatment of enteric infections, and the role of these agents in treating enteric infections. There are a limited number of case reports of quinolones causing arthralgia when used for longer periods. The majority of these have been in children with cystic fibrosis, which is known to be associated with arthralgia, or with the prolonged use of pefloxacin, which is the most potent of the quinolones in initiating arthropathy in animals. The chapter reviews the indications for quinolone use in specific enteric infections or clinical conditions. The study in which patients had the shortest duration of illness, however, was the only one that did not show a reduction in diarrhea duration. The efficacy of antimicrobial prophylaxis of traveler's diarrhea was well established by studies conducted starting in the 1970s with doxycycline, and then with trimethoprim-sulfamethoxazole. There have been at least six studies of fluoroquinolone prophylaxis of traveler's diarrhea. All six studies showed efficacy in reducing the incidence of diarrhea. The protection afforded by prophylaxis in these studies ranged from 76 to 100%, similar to what is found using nonquinolone agents. Still, if someone is going to a particularly high-risk area for a short time, prophylaxis with a fluoroquinolone is likely to markedly diminish the risk of traveler's diarrhea. is another putative cause of gastroenteritis, strains of which are almost all susceptible to quinolones.

Citation: Bennish M. 2003. Treatment and Prophylaxis of Gastroenteritis, p 193-216. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch11
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Acheson, D. W.,, and C. L. Sears. 2001. Dangers of empiric oral ciprofloxacin in the treatment of acute inflammatory diarrhea in children. Pediatr. Infect. Dis. J. 20: 817 818.
2. Adachi, J. A.,, L. Ostrosky-Zeichner,, H. L. DuPont,, and C. D. Ericsson. 2000. Empirical antimicrobial therapy for traveler's diarrhea. Clin. Infect. Dis. 31: 1079 1083.
3. Agalar, C.,, S. Usubutun,, E. Tutuncu,, and R. Turkyilmaz. 1997. Comparison of two regimens for ciprofloxacin treatment of enteric infections. Eur. J. Clin. Microbiol. Infect. Dis. 16: 803 806.
4. Ahmad, F.,, G. Bray,, R. W. Prescott,, S. Aquilla,, and N. F. Lightfoot. 1991. Use of ciprofloxacin to control a Salmonella outbreak in a long-stay psychiatric hospital. J. Hosp. Infect. 17: 171 178.
5. Ahmed, A.,, N. Salahuddin,, T. Ahsan,, S. Afsar,, N. Nasir,, S. Farooqui,, A. N. Chaoudri,, M. A. Akhtar,, I. Agha,, and N. Nagi. 1992. Enoxacin in the treatment of typhoid fever. Clin. Ther. 14: 825 828.
6. Ait-Khaled, A.,, L. Zidane,, A. Amrane,, and R. Aklil. 1990. The efficacy and safety of pefloxacin in the treatment of typhoid fever in Algeria. J. Antimicrob. Chemother. 26: 181 186.
7. Alam, M. N.,, S. A. Haq,, K. K. Das,, P. K. Baral,, M. N. Mazid,, R. U. Siddique,, K. M. Rahman,, Z. Hasan,, M. A. Khan,, and P. Dutta. 1995. Efficacy of ciprofloxacin in enteric fever: comparison of treatment duration in sensitive and multidrug-resistant Salmonella. Am. J. Trop. Med. Hyg. 53: 306 311.
8. Alios, B. M. 2001. Campylobacter jejuni infections: update on emerging issues and trends. Clin. Infect. Dis. 32: 1201 1206.
9. Alsoub, H.,, A. K. Uwaydah,, I. Matar,, M. Zebeib,, and K. M. Elhag. 1997. A clinical comparison of typhoid fever caused by susceptible and multidrug-resistant strains of Salmonella typhi. Br. J. Clin. Bract. 51: 8 10.
10. Anders, B. J.,, B. A. Lauer,, J. W. Paisley,, and L. B. Reller. 1982. Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. Lancet. 1: 131 132.
11. Angulo, F. J.,, K. R. Johnson,, R. V. Tauxe,, and M. L. Cohen. 2000. Origins and consequences of antimicrobial-resistant nontyphoidal Salmonella: implications for the use of fluoroquinolones in food animals. Microb. Drug Resist. 6: 77 83.
12.Anonymous. 1995. Guidelines for the control of epidemics due to Shigella dysenteriae type 1 WHO/CDR/95.4. World Health Organization, Geneva, Switzerland.
13. Anonymous. 2002. Preliminary FoodNet data on the incidence of foodborne illnesses—selected sites, United States, 2001. Morb. Mortal. Wkly. Rep. 51: 325 329.
14. Arnold, K.,, C. S. Hong,, R. Nelwan,, I. Zavala-Trujillo,, A. Kadio,, M. A. Barros,, and S. de Garis. 1993. Randomized comparative study of fleroxacin and chloramphenicol in typhoid fever. Am. J. Med. 94: 195S 200S.
15. Asperilla, M. O.,, R. A. Smego, Jr.,, and L. K. Scott. 1990. Quinolone antibiotics in the treatment of Salmonella infections. Rev. Infect. Dis. 12: 873 889.
16. Attar, A.,, B. Flourie,, J. C. Rambaud,, C. Franchisseur,, P. Ruszniewski,, and Y. Bouhnik. 1999. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology. 117: 794 797.
17. Auckenthaler, R.,, M. Michea-Hamzehpour,, and J. C. Pechere. 1986. In-vitro activity of newer quinolones against aerobic bacteria. J.. Antimicrob. Chemother. 17: 29 39.
18. Bahl, R.,, N. Bhandari,, M. K. Bhan,, M. Saxena,, and A. Bagati. 1996. Efficacy of antimicrobial treatment in nondysenteric persistent diarrhoea in a community setting. Acta Paediatr. 85: 1290 1294.
19. Bassily, S.,, K. C Hyams,, N. A. el-Masry,, Z. Farid,, E. Cross,, A. L. Bourgeois,, E. Ayad,, and R. G. Hibbs. 1994. Shortcourse norfloxacin and trimethoprim-sulfamethoxazole treatment of shigellosis and salmonellosis in Egypt. Am. J. Trop. Med. Hyg. 51: 219 223.
20. Beckebaum, S.,, J. Bircher,, and H. Gallenkamp. 1996. Bioavailability of ciprofloxacin in patients with acute infectious diarrhoe. Eur. J. Clin. Pharmacol. 50: 511 512.
21. Bennish, M. L.,, J. R. Harris,, B. J. Wojtyniak,, and M. Struelens 1990. Death in shigellosis: incidence and risk factors in hospitalized patients. J. Infect. Dis. 161: 500 506.
22. Bennish, M. L.,, M. A. Salam,, R. Haider,, and M. Barza. 1990. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J. Infect. Dis. 162: 711 716.
23. Bennish, M. L.,, M. A. Salam,, M. A. Hossain,, J. Myaux,, E. H. Khan,, J. Chakraborty,, F. Henry,, and C. Ronsmans. 1992. Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin. Infect. Dis. 14: 1055 1060.
24. Bennish, M. L.,, M. A. Salam,, W. A. Khan,, and A. M. Khan. 1992. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann. Intern. Med. 117: 727 734.
25. Bennish, M. L.,, and B. J. Wojtyniak 1991. Mortality due to shigellosis: community and hospital data. Rev. Infect. Dis. 13: S245 S251.
26. Bergan, T.,, S. Lolekha,, M. K. Cheong,, C. L. Poh,, S. Doencham,, and D. Charoenpipop. 1988. Effect of recent antibacterial agents against bacteria causing diarrhoea. Scand. J. Infect. Dis. Suppl. 56: 7 10.
27. Bergan, T.,, S. Lolekha,, M. K. Cheong,, C. L. Poh,, and S. Patancharoen. 1988. Consequences of diarrhoeal disease on the pharmacokinetics of norfloxacin. Scand J. Infect. Dis. Suppl. 56: 11 3.
28. Besser, R. E.,, P. M. Griffin,, and L. Slutsker. 1999. Escherichia coli 0157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease. Annu. Rev. Med. 50: 355 367.
29. Bethell, D. B.,, N. P. Day,, N. M. Dung,, C. McMullin,, H. T. Loan,, D. T. Tam,, L. T. Minh,, N. T. Linh,, N. Q. Dung,, H. Vinh,, A. P. MacGowan,, L. O. White,, and N. J. White. 1996. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob Agents Chemother. 40: 2167 2172.
30. Bethell, D. B.,, T. T. Hien,, L. T. Phi,, N. P. Day,, H. Vinh,, N. M. Duong,, N. V. Len,, L. V. Chuong,, and N. J. White. 1996. Effects on growth of single short courses of fluoroquinolones. Arch. Dis. Child. 74: 44 46.
31. Bhattacharya, K.,, M. K. Bhattacharya,, D. Dutta,, S. Dutta,, M. Deb,, A. Deb,, K. P. Das,, H. Koley,, and G. B. Nair. 1997. Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta. Paediatr. 86: 319 320.
32. Bhattacharya, M. K.,, G. B. Nair,, D. Sen,, M. Paul,, A. Debnath,, A. Nag,, D. Dutta,, P. Dutta,, S. C. Pal,, and S. K. Bhattacharya. 1992. Efficacy of norfloxacin for shigellosis: a double-blind randomised clinical trial. J. Diarrhoeal. Dis. Res. 10: 146 150.
33. Bhattacharya, S. K.,, M. K. Bhattacharya,, P. Dutta,, D. Dutta,, S. P. De,, S. N. Sikdar,, A. Maitra,, A. Dutta,, and S. C. Pal. 1990. Double-blind, randomized, controlled clinical trial of norfloxacin for cholera. Antimicrob. Agents. Chemother. 34: 939 940.
34. Bhattacharya, S. K.,, M. K. Bhattacharya,, P. Dutta,, D. Sen,, R. Rasaily,, A. Moitra,, and S. C. Pal. 1991. Randomized clinical trial of norfloxacin for shigellosis. Am. J. Trop. Med. Hyg. 45: 683 687.
35. Bouckenooghe, A. R.,, Z. D. Jiang,, F. J. De La Cabada,, C. D. Ericsson,, and H. L. DuPont. 2002. Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican Adults and US Travelers in Mexico. J. Travel Med. 9: 137 140.
36. Bryan, J. P.,, C. Waters,, J. Sheffield,, R. E. Krieg,, P. L. Perine,, and K. Wagner 1990. In vitro activities of tosufloxacin, temafloxacin, and A-56620 against pathogens of diarrhea. Antimicrob. Agents Chemother. 34: 368 370.
37. Burkhardt, J. E.,, J. N. Walterspiel,, and U. B. Schaad. 1997. Quinolone arthropathy in animals versus children. Clin. Infect. Dis. 25: 1196 1204.
38. Butler, T.,, S. Lolekha,, C. Rasidi,, A. Kadio,, P. L. del Rosal,, H. Iskandar,, E. Rubinstein,, and G. Pastore. 1993. Treatment of acute bacterial diarrhea: a multicenter international trial comparing placebo with fleroxacin given as a single dose or once daily for 3 days. Am. J. Med. 94: 187S 194S.
39. Cadamy, A. R. 1997. Treating diarrhoea. Patients must be educated about which symptoms require treatment. Br. Med. I.J. 315: 1378.
40. Cao, X. T.,, R. Kneen,, T. A. Nguyen,, D. L. Truong,, N. J. White,, and C. M. Parry. 1999. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. The Dong Nai Pediatric Center Typhoid Study Group. Pediatr. Infect. Dis. J. 18: 245 248.
41. Carlstedt, G.,, P. Dahl,, P. M. Niklasson,, K. Gullberg,, G. Banck,, and G. Kahlmeter. 1990. Norfloxacin treatment of salmonellosis does not shorten the carrier stage. Scand. J. Infect. Dis. 22: 553 556.
42. Chew, S. K.,, E. H. Monteiro,, Y. S. Lim,, and D. M. Allen. 1992. A 7-day course of ciprofloxacin for enteric fever. J. Infect. 25: 267 271.
43. Chin, N. X.,, and H. C. Neu. 1984. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 25: 319 326.
44. Chinh, N. T.,, C. M. Parry,, N. T. Ly,, H. D. Ha,, M. X. Thong,, T. S. Diep,, J. Wain,, N. J. White,, and J. J. Farrar. 2000. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob. Agents Chemother. 44: 1855 1859.
45. Chitnis, V.,, D. Chitnis,, S. Verma,, and N. Hemvani. 1999. Multidrug-resistant Salmonella typhi in India. Lancet 354: 514 515.
46. Chu, Y. W.,, E. T. Houang,, D. J. Lyon,, J. M. Ling,, T. K. Ng,, and A. F. Cheng. 1998. Antimicrobial resistance in Shigella flexneri and Shigella sonnei in Hong Kong, 1986 to 1995. Antimicrob. Agents Chemother. 42: 440 443.
47. Conrad, S.,, M. Oethinger,, K. Kaifel,, G. Klotz,, R. Marre,, and W. V. Kern. 1996. gyrA mutations in high-level fluoroquinolone- resistant clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 38: 443 455.
48. Cristiano, P.,, L. Imparato,, C. Carpinelli,, F. Lauria,, M. R. Iovene,, M. F. Corrado,, P. Maio,, and C. Imperatore. 1995. Pefloxacin versus chloramphenicol in the therapy of typhoid fever. Infection 23: 103 106.
49. Cristiano, P.,, G. Morelli,, V. Briante,, M. R. Iovene,, F. Simioli,, and P. Altucci. 1989. Clinical experience with pefloxacin in the therapy of typhoid fever. Infection 17: 86 87.
50. de la Cabada, F. J.,, H. L. DuPont,, K. Gyr,, and J. J. Mathewson. 1992. Antimicrobial therapy of bacterial diarrhea in adult residents of Mexico—lack of an effect. Digestion 53: 134 141.
51. De Mol, P.,, T. Mets,, R. Lagasse,, J. Vandepitte,, A. Mutwewingabo,, and J. P. Butzler. 1987. Treatment of bacillary dysentery: a comparison between enoxacin and nalidixic acid. J. Antimicrob. Chemother. 19: 695 698.
52. Diridl, G.,, H. Pichler,, and D. Wolf. 1986. Treatment of chronic salmonella carriers with ciprofloxacin. Eur. J. Clin. Microbiol. 5: 260 261.
53. Doganci, L.,, H. Gun,, M. Baysallar,, A. Albay,, E. Cinar,, and T. Haznedaroglu 1995. Short-term quinolones for successful eradication of multiply resistant Vibrio cholerae in adult patients. Scand. J. Infect. Dis. 27: 425 426.
54. Dryden, M. S.,, R. J. Gabb,, and S. K. Wright. 1996. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin. Infect. Dis. 22: 1019 1025.
55. DuPont, H. L.,, C. D. Ericsson,, J. J. Mathewson,, and M. W. DuPont. 1992. Five versus three days of ofloxacin therapy for traveler's diarrhea: a placebo-controlled study. Antimicrob. Agents Chemother. 36: 87 91.
56. DuPont, H. L.,, Z. D. Jiang,, C. D. Ericsson,, J. A. Adachi,, J. J. Mathewson,, M. W. DuPont,, E. Palazzini,, L. M. Riopel,, D. Ashley,, and F. Martinez-Sandoval. 2001. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis. 33: 1807 1815.
57. Dutta, D.,, S. K. Bhattacharya,, M. K. Bhattacharya,, A. Deb,, M. Deb,, B. Manna,, A. Moitra,, A. K. Mukhopadhyay,, and G. B. Nair. 1996. Efficacy of norfloxacin and doxycycline for treatment of vibrio cholerae 0139 infection. J. Antimicrob. Chemother. 37: 575 581.
58. Dutta, P.,, U. Mitra,, S. Dutta,, A. De,, M. K. Chatterjee,, and S. K. Bhattacharya. 2001. Ceftriaxone therapy in ciprofloxacin treatment failure typhoid fever in children. Indian J. Med. Res. 113: 210 213.
59. Dutta, P.,, R. Rasaily,, M. R. Saha,, U. Mitra,, S. K. Bhattacharya,, M. K. Bhattacharya,, and M. Lahiri. 1993. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob. Agents Chemother. 37: 1197 1199.
60. Echevarria, J.,, C. Seas,, C. Carrillo,, R. Mostorino,, R. Ruiz,, and E. Gotuzzo. 1995. Efficacy and tolerability of ciprofloxacin prophylaxis in adult household contacts of patients with cholera. Clin. Infect. Dis. 20: 1480 1484.
61. Ellis-Pegler, R. B.,, L. K. Hyman,, R. J. Ingram,, and M. McCarthy. 1995. A placebo controlled evaluation of lomefloxacin in the treatment of bacterial diarrhoea in the community. J. Antimicrob. Chemother. 36: 259 263.
62. Endtz, H. P.,, R. P. Mouton,, T. van der Reyden,, G. J. Ruijs,, M. Biever,, and B. van Klingeren. 1990. Fluoroquinolone resistance in Campylobacter spp isolated from human stools and poultry products. Lancet 335: 787.
63. Endtz, H. P.,, G. J. Ruijs,, B. van Klingeren,, W. H. Jansen,, T. van der Reyden,, and R. P. Mouton. 1991. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J. Antimicrob. Chemother. 27: 199 208.
64. Engberg, J.,, F. M. Aarestrup,, D. E. Taylor,, P. Gerner-Smidt,, and I. Nachamkin. 2001. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg. Infect. Dis. 7: 24 34.
65. Ericsson, C. D.,, H. L. DuPont,, and J. J. Mathewson. 1997. Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler's diarrhea. J. Travel Med. 4: 3 7.
66. Ericsson, C. D.,, P. C. Johnson,, H. L. Dupont,, D. R. Morgan,, J. A. Bitsura,, and F. J. de la Cabada. 1987. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. Ann. Intern. Med. 106: 216 220.
67. Esposito, S.,, G. B. Gaeta,, D. Galante,, and D. Barba. 1985. Successful treatment with ciprofloxacin of Salmonella typhimurium infection in an immunocompromised host. Infection 13: 288.
68. Essers, B.,, A. P. Burnens,, F. M. Lanfranchini,, S. G. Somaruga,, R. O. von Vigier,, U. B. Schaad,, C. Aebi,, and M. G. Bianchetti. 2000. Acute community-acquired diarrhea requiring hospital admission in Swiss children. Clin. Infect. Dis. 31: 192 196.
69. Farthing, M.,, R. Feldman,, R. Finch,, R. Fox,, C. Leen,, B. Mandal,, P. Moss,, D. Nathwani,, F. Nye,, A. Percival,, R. Read,, L. Ritchie,, W. T. Todd,, and M. Wood. 1996. The management of infective gastroenteritis in adults. A consensus statement by an expert panel convened by the British Society for the Study of Infection. J. Infect. 33: 143 152.
70. Felmingham, D.,, and M. J. Robbins. 1992. In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens. Diagn. Microbiol. Infect. Dis. 25: 339 343.
71. Felmingham, D.,, M. J. Robbins,, K. Ingley,, I. Mathias,, H. Bhogal,, A. Leakey,, G. L. Ridgway,, and R. N. Gruneberg. 1997. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. 39: 43 49.
72. Fernandez-Roblas, R.,, F. Cabria,, J. Esteban,, J. C. Lopez,, I. Gadea,, and F. Soriano. 2000. In vitro activity of gemifloxacin (SB-265805) compared with 14 other antimicrobials against intestinal pathogens. J. Antimicrob. Chemother. 46: 1023 1027.
73. Ferreccio, C.,, J. G. Morris, Jr.,, C. Valdivieso,, I. Prenzel,, V. Sotomayor,, G. L. Drusano,, and M. M. Levine 1988. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J. Infect. Dis. 157: 1235 1239.
74. Frost, J. A.,, A. Kelleher,, and B. Rowe. 1996. Increasing ciprofloxacin resistance in salmonellas in England and Wales 1991-1994. J. Antimicrob. Chemother. 37: 85 91.
75. Garcia-Rodriguez, J. A.,, M. J. Fresnadillo,, M. I. Garcia,, E. Garcia-Sanchez,, J. E. Garcia-Sanchez,, and I. Trujillano. 1995. Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance. Eur. J. Clin. Microbiol. Infect. Dis. 14: 456 459.
76. Garcia-Rodriguez, J. A.,, J. E. GarciaSanchez,, M. I. GarciaGarcia,, M. J. Fresnadillo,, I. Trujillano,, and E. GarciaSanchez 1994. In-vitro activity of four new fluoroquinolones. J. Antimicrob. Chemother. 34: 53 64.
77. Gaudreau, C.,, and H. Gilbert. 1998. Antimicrobial resistance of clinical strains of Campylobacter jejuni subsp. jejuni isolated from 1985 to 1997 in Quebec, Canada. Antimicrob. Agents Chemother. 42: 2106 2108.
78. Gaunt, P. N.,, and L. J. Piddock. 1996. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J. Antimicrob. Chemother. 37: 747 757.
79. Gendrel, D.,, J. L. Moreno,, M. Nduwimana,, C. Baribwira,, and J. Raymond. 1997. One-dose treatment with pefloxacin for infection due to multidrug-resistant Shigella dysenteriae type 1 in Burundi. Clin. Infect. Dis. 24: 83.
80. Gibreel, A.,, E. Sjogren,, B. Kaijser,, B. Wretlind,, and O. Skold. 1998. Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC. Antimicrob. Agents Chemother. 42: 3276 3278.
81. Girgis, N. I.,, T. Butler,, R. W. Frenck,, Y. Sultan,, F. M. Brown,, D. Tribble,, and R. Khakhria. 1999. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob. Agents Chemother. 43: 1441 1444.
82. Glandt, M.,, J. A. Adachi,, J. J. Mathewson,, Z. D. Jiang,, D. DiCesare,, D. Ashley,, C. D. Ericsson,, and H. L. DuPont. 1999. Enteroaggregative Escherichia coli as a cause of traveler's diarrhea: clinical response to ciprofloxacin. Clin. Infect. Dis. 29: 335 338.
83. Goldstein, F. W.,, J. C. Chumpitaz,, J. M. Guevara,, B. Papadopoulou,, J. F. Acar,, and J. F. Vieu. 1986. Plasmidmediated resistance to multiple antibiotics in Salmonella typhi. J. Infect. Dis. 153: 261 266.
84. Gomi, H.,, Z. D. Jiang,, J. A. Adachi,, D. Ashley,, B. Lowe,, M. P. Verenkar,, R. Steffen,, and H. L. DuPont. 2001. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob. Agents Chemother. 45: 212 216.
85. Goodman, L. J.,, R. M. Fliegelman,, G. M. Trenholme,, and R. L. Kaplan. 1984. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens. Antimicrob. Agents Chemother. 25: 504 506.
86. Goodman, L. J.,, G. M. Trenholme,, R. L. Kaplan,, J. Segreti,, D. Hines,, R. Petrak,, J. A. Nelson,, K. W. Mayer,, W. Landau,, G. W. Parkhurst, et al. 1990. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch. Intern. Med. 150: 541 546.
87. Goossens, H.,, P. De Mol,, H. Coignau,, J. Levy,, O. Grados,, G. Ghysels,, H. Innocent,, and J. P. Butzler. 1985. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrob. Agents Chemother. 27: 388 392.
88. Gorbach, S. L. 1997. Treating diarrhoea. Br. Med. J. 314: 1776 1777.
89. Gotuzzo, E.,, J. G. Guerra,, L. Benavente,, J. C. Palomino,, C. Carrillo,, J. Lopera,, F. Delgado,, D. R. Nalin,, and J. Sabbaj. 1988. Use of norfloxacin to treat chronic typhoid carriers. J. Infect. Dis. 157: 1221 1225.
90. Gotuzzo, E.,, R. A. Oberhelman,, C. Maguina,, S. J. Berry,, A. Yi,, M. Guzman,, R. Ruiz,, R. Leon-Barua,, and R. B. Sack. 1989. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults. Antimicrob. Agents Chemother. 33: 1101 1104.
91. Gotuzzo, E.,, C. Seas,, J. Echevarria,, C. Carrillo,, R. Mostorino,, and R. Ruiz. 1995. Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin. Infect. Dis. 20: 1485 1490.
92. Griffiths, N. M.,, B. H. Hirst,, and N. L. Simmons. 1994. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J. Pharmacol. Exp. Ther. 269: 496 502.
93. Gruneberg, R. N.,, D. Felmingham,, M. D. O'Hare,, M. J. Robbins,, K. Perry,, R. A. Wall,, and G. L. Ridgway. 1988. The comparative in-vitro activity of ofloxacin. J. Antimicrob. Chemother. 22: 9 19.
94. Guerrant, R. L.,, T. Van Gilder,, T. S. Steiner,, N. M. Thielman,, L. Slutsker,, R. V. Tauxe,, T. Hennessy,, P. M. Griffin,, H. DuPont,, R. B. Sack,, P. Tarr,, M. Neill,, I. Nachamkin,, L. B. Reller,, M. T. Osterholm,, M. L. Bennish,, and L. K. Pickering. 2001. Practice guidelines for the management of infectious diarrhea. Clin. Infect. Dis. 32: 331 351.
95. Hajji, M.,, N. el Mdaghri,, M. Benbachir,, K. M. el Filali,, and H. Himmich. 1988. Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults. Eur. J. Clin. Microbiol. Infect. Dis. 7: 361 363.
96. Hakanen, A.,, P. Kotilainen,, P. Huovinen,, H. Helenius,, and A. Siitonen. 2001. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg. Infect. Dis. 7: 996 1003.
97. Hakanen, A.,, P. Kotilainen,, J. Jalava,, A. Siitonen,, and P. Huovinen. 1999. Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J. Clin. Microbiol. 37: 3572 3577.
98. Hakanen, A.,, A. Siitonen,, P. Kotilainen,, and P. Huovinen. 1999. Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997. J. Antimicrob. Chemother. 43: 145 148.
99. Haltalin, K. C.,, J. D. Nelson,, and H. T. Kusmiesz. 1973. Comparative efficacy of nalidixic acid and ampicillin for severe shigellosis. Arch. Dis. Child. 48: 305 312.
100. Haltalin, K.C.,, J. D. Nelson,, R. Ring III,, M. Sladoje,, and L. V. Hinton. 1967. Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo. J. Pediatr. 70: 970 981.
101. Hansson, H. B.,, G. Barkenius,, S. Cronberg,, and I. Juhlin. 1981. Controlled comparison of nalidixic acid or lactulose with placebo in shigellosis. Scand. J. Infect. Dis. 13: 191 193.
102. Hassan, A.,, M. F. Wahab,, Z. Farid,, and A. S. el-Rooby. 1970. Treatment of typhoid and paratyphoid fever with nalidixic acid. J. Trop. Med. Hyg. 73: 145 147.
103. Heck, J. E.,, J. L. Staneck,, M. B. Cohen,, L. S. Weckbach,, R. A. Giannella,, J. Hawkins,, and R. Tosiello. 1994. Prevention of Travelers' Diarrhea: ciprofloxacin versus trimethoprim/ sulfamethoxazole in adult volunteers working in Latin America and the Caribbean. J. Travel Med. 1: 136 142.
104. Helms, M.,, P. Vastrup,, P. Gerner-Smidt,, and K. Molbak. 2002. Excess mortality associated with antimicrobial drugresistant Salmonella typhimurium. Emerg. Infect. Dis. 8: 490 495.
105. Heseltine, P. N.,, D. M. Causey,, M. D. Appleman,, M. L. Corrado,, and J. M. Leedom. 1988. Norfloxacin in the eradication of enteric infections in AIDS patients. Eur. J. Cancer Clin. Oncol. 24: S25 S8.
106. Hoge, C. W.,, J. M. Gambel,, A. Srijan,, C. Pitarangsi,, and P. Echeverria. 1998. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin. Infect. Dis. 26: 341 345.
107. Hoogkamp-Korstanje, J. A. 1987. Antibiotics in Yersinia enterocolitica infections. J. Antimicrob. Chemother. 20: 123 131.
108. Hoogkamp-Korstanje, J. A.,, H. Moesker,, and G. A. Bruyn. 2000. Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis. Ann. Rheum. Dis. 59: 914 917.
109. Hooper, D. C. 2000. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30: 243 254.
110. Horiuchi, S.,, Y. Inagaki,, N. Yamamoto,, N. Okamura,, Y. Imagawa,, and R. Nakaya. 1993. Reduced susceptibilities of Shigella sonnei strains isolated from patients with dysentery to fluoroquinolones. Antimicrob. Agents Chemother. 37: 2486 2489.
111. Hung, C. C.,, S. M. Hsieh,, C. F. Hsiao,, M. Y. Chen,, and W. H. Sheng. 2001. Risk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy. AIDS 15: 645 647.
112. Inglesfield, J. W. 1997. Treating diarrhoea. Advocating widespread use of antimicrobial agents has economic implications. Br. Med. J. 315: 1379.
113. Isenbarger, D. W.,, C. W. Hoge,, A. Srijan,, C. Pitarangsi,, N. Vithayasai,, L. Bodhidatta,, K. W. Hickey,, and P. D. Cam. 2002. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg. Infect. Dis. 8: 175 180.
114. Jesudason, M. V.,, B. Malathy,, and T. J. John. 1996. Trend of increasing levels of minimum inhibitory concentration of ciprofloxacin to Salmonella typhi Indian. J. Med. Res. 103: 247 249.
115. Jiang, Z. D.,, B. Lowe,, M. P. Verenkar,, D. Ashley,, R. Steffen,, N. Tornieporth,, F. von Sonnenburg,, P. Waiyaki,, and H. L. DuPont. 2002. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J. Infect. Dis. 185: 497 502.
116. Johnson, P. C.,, C. D. Ericsson,, D. R. Morgan,, H. L. Dupont,, and F. J. Cabada. 1986. Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin. Antimicrob. Agents Chemother. 30: 671 674.
117. Kampfer, P.,, C. Christmann,, J. Swings,, and G. Huys. 1999. In vitro susceptibilities of Aeromonas genomic species to 69 antimicrobial agents. Syst. Appl Microbiol. 22: 662 669.
118. Kapil, A.,, S. Sood,, N. R. Dash,, B. K. Das,, and P. Seth. 1999. Ciprofloxacin in typhoid fever. Lancet 354: 164.
119. Khan, M. A.,, Z. Hayat,, and A. Sadick. 1994. Ofloxacin in the treatment of typhoid fever resistant to chloramphenicol and amoxicillin. Clin. Ther. 16: 815 818.
120. Khan, W. A.,, M. Begum,, M. A. Salam,, P. K. Bardhan,, M. R. Islam,, and D. Mahalanabis. 1995. Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Trans. R. Soc. Trop. Med. Hyg. 89: 103 106.
121. Khan, W. A.,, M. L. Bennish,, C. Seas,, E. H. Khan,, A. Ronan,, U. Dhar,, W. Busch,, and M. A. Salam. 1996. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 348: 296 300.
122. Khan, W. A.,, D. Saha,, A. Rahman,, M. A. Salam,, J. Bogaerts,, and M. L. Bennish. Randomised, double-blinded comparison of single-dose azithromycin and 12 dose, 3-day erythromycin therapy for childhood cholera Lancet, in press.
123. Khan, W. A.,, C. Seas,, U. Dhar,, M. A. Salam,, and M. L. Bennish. 1997. Treatment of shigellosis. V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann. Intern. Med. 126: 697 703.
124. Kimmitt, P. T.,, C. R. Harwood,, and M. R. Barer. 1999. Induction of type 2 Shiga toxin synthesis in Escherichia coli 0157 by 4-quinolones. Lancet 353: 1588 1589.
125. Kimmitt, P. T.,, C. R. Harwood,, and M. R. Barer. 2000. Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg. Infect. Dis. 6: 458 465.
126. Kubin, R. 1993. Safety and efficacy of ciprofloxacin in paediatric patients—review. Infection 21: 413 421.
127. Kuschner, R. A.,, A. F. Trofa,, R. J. Thomas,, C. W. Hoge,, C. Pitarangsi,, S. Amato,, R. P. Olafson,, P. Echeverria,, J. C. Sadoff,, and D. N. Taylor. 1995. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. C/m. Infect. Dis. 21: 536 541.
128. Laing, R. B.,, C. Lee,, and C. L. Leen. 1996. An audit of the clinical features and use of antimicrobials in adult diarrhoea. J. Infect. 32: 17 21.
129. Leibovitz, E.,, J. Janco,, L. Piglansky,, J. Press,, P. Yagupsky,, H. Reinhart,, I. Yaniv,, and R. Dagan. 2000. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr. Infect. Dis. J. 19: 1060 1067.
130. Leigh, D. A.,, B. Walsh,, K. Harris,, P. Hancock,, and G. Travers. 1988. Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. J. Antimicrob. Chemother. 22: 115 125.
131. Leung, D.,, and P. Venkatesan. 1997. Treating diarrhoea. More evidence is needed that widespread use of quinolones will benefit patients. Br. Med. J. 315: 1379.
132. Liao, W. C.,, and M. S. Cappell. 1989. Treatment with ciprofloxacin of Aeromonas hydrophila associated colitis in a male with antibodies to the human immunodeficiency virus. J. Clin. Gastroenterol. 11: 552 554.
133. Lindenbaum, J.,, W. B. Greenough,, and M. R. Islam. 1967. Antibiotic therapy of cholera. Bull W. H. O. 36: 871 883.
134. Lindenbaum, J.,, W. B. Greenough,, and M. R. Islam. 1967. Antibiotic therapy of cholera in children. Bull. W. H. O. 37: 529 538.
135. Ling, J.,, K. M. Kam,, A. W. Lam,, and G. L. French. 1988. Susceptibilities of Hong Kong isolates of multiply resistant Shigella spp. to 25 antimicrobial agents, including ampicillin plus sulbactam and new 4-quinolones. Antimicrob. Agents. Chemother. 32: 20 23.
136. Lipsky, B. A.,, and C. A. Baker. 1999. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis. 28: 352 364.
137. Loffler, A.,, and H. Grafvon Westphalen. 1986. Successful treatment of chronic Salmonella excretor with ofloxacin. Lancet 1: 1206.
138. Lolekha, S.,, S. Patanachareon,, B. Thanangkul,, and S. Vibulbandhitkit. 1988. Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study. Scand. J. Infect. Dis. Suppl. 56: 35 45.
139. Lolekha, S.,, S. Vibulbandhitkit,, and P. Poonyarit. 1991. Response to antimicrobial therapy for shigellosis in Thailand. Rev. Infect. Dis. 13: S342 S346.
140. Malorny, B.,, A. Schroeter,, and R. Helmuth. 1999. Incidence of quinolone resistance over the period 1986 to 1998 in veterinary Salmonella isolates from Germany. Antimicrob. Agents Chemother. 43: 2278 2282.
141. Mandal, B. K.,, M. E. Ellis,, E. M. Dunbar,, and K. Whale. 1984. Double-blind placebo-controlled trial of erythromycin in the treatment of clinical Campylobacter infection. J. Antimicrob. Chemother. 13: 619 623.
142. Matsushiro, A.,, K. Sato,, H. Miyamoto,, T. Yamamura,, and T. Honda. 1999. Induction of prophages of enterohemorrhagic Escherichia coli 0157:H7 with norfloxacin. J. Bacteriol. 181: 2257 2260.
143. Mattila, L.,, H. Peltola,, A. Siitonen,, H. Kyronseppa,, I. Simula,, and M. Kataja. 1993. Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebocontrolled study during two seasons. Clin. Infect. Dis. 17: 779 782.
144. McDermott, P. F.,, S. M. Bodeis,, L. L. English,, D. G. White,, R. D. Walker,, S. Zhao,, S. Simjee,, and D. D. Wagner. 2002. Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones. J. Infect. Dis. 185: 837 840.
145. Mead, P. S.,, L. Slutsker,, V. Dietz,, L. F. McCaig,, J. S. Bresee,, C. Shapiro,, P. M. Griffin,, and R. V. Tauxe. 1999. Foodrelated illness and death in the United States. Emerg. Infect. Dis. 5: 607 625.
146. Meskin, S.,, M. S. Jacob,, R. Macaden,, J. S. Keystone,, P. E. Kozarsky,, A. N. Ramachadran,, and B. Metchock. 1992. Short-course treatment of typhoid fever with ciprofloxacin in south India. Trans. R. Soc. Trop. Med. Hyg. 86: 446 447.
147. Mirelis, B.,, E. Miro,, F. Navarro,, C. A. Ogalla,, J. Bonal,, and G. Prats. 1993. Increased resistance to quinolone in Catalonia, Spain. Diagn. Microbiol. Infect. Dis. 16: 137 139.
148. Molbak, K.,, D. L. Baggesen,, F. M. Aarestrup,, J. M. Ebbesen,, J. Engberg,, K. Frydendahl,, P. Gerner-Smidt,, A. M. Petersen,, and H. C. Wegener. 1999. An outbreak of multidrug- resistant, quinolone-resistant Salmonella enterica serotype typhimurium DTI 04. N. Engl. J. Med. 341: 1420 1425.
149. Molbak, K.,, P. Gerner-Smidt,, and H. C. Wegener. 2002. Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg. Infect. Dis. 8: 514 515.
150. Moolasart, P.,, B. Eampokalap,, and S. Supaswadikul. 1998. Comparison of the efficacy of tetracycline and norfloxacin in the treatment of acute severe watery diarrhea. Southeast. Asian. } . Trop. Med. Public Health. 29: 108 111.
151. Moore, J. E.,, M. Crowe,, N. Heaney,, and E. Crothers. 2001. Antibiotic resistance in Campylobacter spp. isolated from human faeces (1980-2000) and foods (1997-2000) in Northern Ireland: an update. J. Antimicrob. Chemother. 48: 455 457.
152. Murdoch, D. A.,, N. Banatvaia,, A. Bone,, B. I. Shoismatulloev,, L. R. Ward,, E. J. Threlfall,, and N. A. Banatvaia. 1998. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 351: 339.
153. Murphy, G. S.,, L. Bodhidatta,, P. Echeverria,, S. Tansuphaswadikul,, C. W. Hoge,, S. Imlarp,, and K. Tamura. 1993. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann. Intern. Med. 118: 582 586.
154. Murphy, G. S., Jr.,, P. Echeverria,, L. R. Jackson,, M. K. Arness,, C. LeBron,, and C. Pitarangsi. 1996. Ciprofloxacinand azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin. Infect. Dis. 22: 868 869.
155. Murray, B. E.,, T. Alvarado,, K. H. Kim,, M. Vorachit,, P. Jayanetra,, M. M. Levine,, I. Prenzel,, M. Fling,, L. Elwell,, G. H. McCracken, et al. 1985. Increasing resistance to trimethoprim-sulfamethoxazole among isolates of Escherichia coli in developing countries. J. Infect. Dis. 152: 1107 1113.
156. Musafija, A.,, A. Barzilai,, J. Ramon,, and E. Rubinstein. 1998. Effect of cholera toxin on intestinal elimination of ciprofloxacin in rabbits. Antimicrob. Agents Chemother. 42: 473 474.
157. Musafija, A.,, J. Ramon,, Y. Shtelman,, G. Yoseph,, B. Rubinovitz,, S. Segev,, and E. Rubinstein. 2000. Trans-epithelial intestinal elimination of moxifloxacin in rabbits. J. Antimicrob. Chemother. 45: 803 805.
158. Musafija, A.,, Y. Shtelman,, J. Ramon,, M. Volk,, S. Segev,, and E. Rubinstein. 2001. The effect of Escherichia coli heat-stable toxin on the trans-epithelial intestinal elimination of ciprofloxacin in the rabbit. J. Antimicrob. Chemother. 47: 697 699.
159. Nathwani, D.,, R. B. Laing,, G. Harvey,, and C. C. Smith. 1991. Treatment of symptomatic enteric aeromonas hydrophila infection with ciprofloxacin. Scand. J. Infect. Dis. 23: 653 654.
160. Neill, M. A.,, S. M. Opal,, J. Heelan,, R. Giusti,, J. E. Cassidy,, R. White,, and K. H. Mayer. 1991. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann. Intern. Med. 114: 195 199.
161. Nelson, M. R.,, D. C. Shanson,, D. A. Hawkins,, and B. G. Gazzard. 1992. Salmonella, Campylobacter and Shigella in HIV-seropositive patients. AIDS 6: 1495 1498.
162. Nelwan, R. H.,, Hendarwanto,, I. Zulkarnain,, J. Gunawan,, I. Supandiman,, H. Yusuf,, P. Soedjana,, and A. Syahroni. 1995. A comparative study of short course ciprofloxacin treatment in typhoid and paratyphoid fever. Drugs 49: 463 465.
163. Nguyen, T. C.,, T. Solomon,, X. T. Mai,, T. L. Nguyen,, T. T. Nguyen,, J. Wain,, S. D. To,, M. D. Smith,, N. P. Day,, T. P. Le,, C. Parry,, and N. J. White. 1997. Short courses of ofloxacin for the treatment of enteric fever. Trans. R. Soc. Trop. Med. Hyg. 91: 347 349.
164. Noguerado, A.,, I. Garcia-Polo,, T. Isasia,, M. L. Jimenez,, P. Bermudez,, J. Pita,, and R. Gabriel. 1995. Early single dose therapy with ofloxacin for empirical treatment of acute gastroenteritis: a randomised, placebo-controlled double-blind clinical trial. J. Antimicrob. Chemother. 36: 665 672.
165. O'Hare, M. D.,, D. Felmingham,, G. L. Ridgway,, and R. N. Gruneberg. 1985. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens. Drugs Exp. Clin. Res. 11: 253 257.
166. Olsen, S. J.,, E. E. DeBess,, T. E. McGivern,, N. Marano,, T. Eby,, S. Mauvais,, V. K. Balan,, G. Zirnstein,, P. R. Cieslak,, and F. J. Angulo. 2001. A nosocomial outbreak of fluoroquinolone- resistant salmonella infection. N. Engl. J. Med. 344: 1572 1579.
167. Olsson-Liljequist, B.,, and R. Mollby. 1990. In vitro activity of norfloxacin and other antibacterial agents against gastrointestinal pathogens isolated in Sweden. APMIS 98: 150 155.
168. Parry, C.,, J. Wain,, N. T. Chinh,, H. Vinh,, and J. J. Farrar. 1998. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 351: 1289.
169. Parry, H.,, A. J. Howard,, O. P. Galpin,, and S. P. Hassan. 1994. The prophylaxis of travellers' diarrhoea; a double blind placebo controlled trial of ciprofloxacin during a Himalayan expedition. J. Infect. 28: 337 338.
170. Pavia, A. T.,, C. R. Nichols,, D. P. Green,, R. V. Tauxe,, S. Mottice,, K. D. Greene,, J. G. Wells,, R. L. Siegler,, E. D. Brewer,, D. Hannon, et al. 1990. Hemolytic-uremic syndrome during an outbreak of Escherichia coli 0157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J. Pediatr. 116: 544 551.
171. Pechere, J. C. 1993. Quinolones in intracellular infections. Drugs 45: 29 36.
172. Pecquet, S.,, A. Andremont,, and C. Tancrede. 1987. Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob. Agents Chemother. 31: 124 125.
173. Pecquet, S.,, S. Ravoire,, and A. Andremont. 1990. Faecal excretion of ciprofloxacin after a single oral dose and its effect on faecal bacteria in healthy volunteers. J. Antimicrob. Chemother. 26: 125 129.
174. Petruccelli, B. P.,, G. S. Murphy,, J. L. Sanchez,, S. Walz,, R. DeFraites,, J. Gelnett,, R. L. Haberberger,, P. Echeverria,, and D. N. Taylor. 1992. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J. Infect. Dis. 165: 557 560.
175. Pichler, H.,, G. Diridl,, and D. Wolf. 1986. Ciprofloxacin in the treatment of acute bacterial diarrhea: a double blind study. Eur. J. Clin. Microbiol. 5: 241 243.
176. Pichler, H. E.,, G. Diridl,, K. Stickler,, and D. Wolf. 1987. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am. J. Med. 82: 329 332.
177. Piddock, L. J. 1995. Quinolone resistance and Campylobacter spp. J. Antimicrob. Chemother. 36: 891 898.
178. Pitkajarvi, T.,, E. Kujanne,, I. Sillantaka,, and J. Lumio. 1996. Norfloxacin and Salmonella excretion in acute gastroenteritis— a 6-month follow-up study. Scand. J. Infect. Dis. 28: 177 180.
179. Pradhan, K. M.,, N. K. Arora,, A. Jena,, A. K. Susheela,, and M. K. Bhan. 1995. Safety of ciprofloxacin therapy in children: magnetic resonance images, body fluid levels of fluoride and linear growth. Acta. Paediatr. 84: 555 560.
180. Prats, G.,, B. Mirelis,, T. Llovet,, C. Munoz,, E. Miro,, and F. Navarro. 2000. Antibiotic resistance trends in enteropathogenic bacteria isolated in 1985-1987 and 1995-1998 in Barcelona. Antimicrob. Agents Chemother. 44: 1140 1145.
181. Rademaker, C. M.,, I. M. Hoepelman,, M. J. Wolfhagen,, H. Beumer,, M. Rozenberg-Arska,, and J. Verhoef. 1989. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur. J. Clin. Microbiol. Infect. Dis. 8: 690 694.
182. Ramon, J.,, M. Ben-Haim,, M. Shabtai,, and E. Rubinstein. 2001. Transepithelial intestinal excretion of ciprofloxacin in humans. Clin. Infect. Dis. 32: 822 823.
183. Ramon, J.,, S. Dautrey,, R. Farinoti,, C. Carbon,, and E. Rubinstein. 1996. Excretion of ciprofloxacin into the large bowel of the rabbit. Antimicrob. Agents Chemother. 40: 11 13.
184. Ramon, J.,, S. Dautrey,, R. Farinoti,, C. Carbon,, and E. Rubinstein. 1994. Intestinal elimination of ciprofloxacin in rabbits. Antimicrob. Agents Chemother. 38: 757 760.
185. Rathish, K. C.,, M. R. Chandrashekar,, and C. N. Nagesha. 1995. An outbreak of multidrug resistant typhoid fever in Bangalore. Indian J. Pediatr. 62: 445 448.
186. Reid, T.,, and C. Smith. 1987. Ciprofloxacin treatment of chronic Salmonella excretors. Chemioterapia 6: 485 486.
187. Rendi-Wagner, P.,, and H. Kollaritsch. 2002. Drug prophylaxis for travelers' diarrhea. Clin. Infect. Dis. 34: 628 633.
188. Ries, A. A.,, J. G. Wells,, D. Olivola,, M. Ntakibirora,, S. Nyandwi,, M. Ntibakivayo,, C. B. Ivey,, K. D. Greene,, F. C. Tenover,, S. P. Wahlquist, et al. 1994. Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention. J. Infect. Dis. 169: 1035 1041.
189. Robins-Browne, R. M.,, M. K. Mackenjee,, M. N. Bodasing,, and H. M. Coovadia. 1983. Treatment of Campylobacterassociated enteritis with erythromycin. Am. J. Dis. Child. 137: 282 285.
190. Rogerie, F.,, D. Ott,, J. Vandepitte,, L. Verbist,, P. Lemmens,, and I. Habiyaremye. 1986. Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults. Antimicrob. Agents Chemother. 29: 883 886.
191. Rubinstein, E.,, S. Dautrey,, R. Farinoti,, L. St Julien,, J. Ramon,, and C. Carbon. 1995. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats. Antimicrob. Agents Chemother. 39: 99 102.
192. Rubinstein, E.,, L. St Julien,, J. Ramon,, S. Dautrey,, R. Farinotti,, J. F. Huneau,, and C. Carbon. 1994. The intestinal elimination of ciprofloxacin in the rat. J. Infect. Dis. 169: 218 221.
193. Ruiz, J.,, J. Gomez,, M. M. Navia,, A. Ribera,, J. M. Sierra,, F. Marco,, J. Mensa,, and J. Vila. 2002. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn. Microbiol. Infect. Dis. 42: 257 261.
194. Ruiz, J.,, P. Goni,, F. Marco,, F. Gallardo,, B. Mirelis,, T. Jimenez De Anta,, and J. Vila. 1998. Increased resistance to quinolones in Campylobacter jejuni: a genetic analysis of gyrA gene mutations in quinolone-resistant clinical isolates. Microbiol. Immunol. 42: 223 226.
195. Ryan, E. T.,, U. Dhar,, W. A. Khan,, M. A. Salam,, A. S. Faruque,, G. J. Fuchs,, S. B. Calderwood,, and M. L. Bennish. 2000. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am. J. Trop. Med. Hyg. 63: 12 20.
196. Saenz, Y.,, M. Zarazaga,, M. Lantero,, M. J. Gastanares,, F. Baquero,, and C. Torres. 2000. Antibiotic resistance in Campylobacter strains isolated from animals, foods, and humans in Spain in 1997-1998. Antimicrob. Agents Chemother. 44: 267 271.
197. Salam, I.,, P. Katelaris,, S. Leigh-Smith,, and M. J. Farthing. 1994. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet. 344: 1537 1539.
198. Salam, M. A.,, and M. L. Bennish. 1991. Antimicrobial therapy for shigellosis. Rev. Infect. Dis. 13: S332 S341.
199. Salam, M. A.,, and M. L. Bennish. 1988. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J. Pediatr. 113: 901 907.
200. Salam, M. A.,, U. Dhar,, W. A. Khan,, and M. L. Bennish. 1998. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 352: 522 527.
201. Salazar-Lindo, E.,, R. B. Sack,, E. Chea-Woo,, B. A. Kay,, Z. A. Piscoya,, R. Leon-Barua,, and A. Yi. 1986. Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children. J. Pediatr. 109: 355 360.\
202. Sammalkorpi, K.,, J. Lahdevirta,, T. Makela,, and T. Rostila. 1987. Treatment of chronic Salmonella carriers with ciprofloxacin. Lancet 2: 164 165.
203. San Joaquin, V. H.,, R. K. Scribner,, D. A. Pickett,, and D. F. Welch. 1986. Antimicrobial susceptibility of Aeromonas species isolated from patients with diarrhea. Antimicrob. Agents Chemother. 30: 794 795.
204. Sanchez, C.,, E. Garcia-Restoy,, J. Garau,, F. Bella,, N. Freixas,, M. Simo,, J. Lite,, P. Sanchez,, E. Espejo,, E. Cobo, et al. 1993. Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J. Infect. Dis. 168: 1304 1307.
205. Sarma, P. S.,, and P. Durairaj. 1991. Randomized treatment of patients with typhoid and paratyphoid fevers using norfloxacin or chloramphenicol. Trans. R. Soc. Trop. Med. Hyg. 85: 670 671.
206. Scott, D. A.,, R. L. Haberberger,, S. A. Thornton,, and K. C. Hyams. 1990. Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. Am. J. Trop. Med. Hyg. 42: 160 164.
207. Secmeer, G.,, G. Kanra,, G. Figen,, O. Akan,, M. Ceyhan,, and Z. Ecevit. 1997. Ofloxacin versus co-trimoxazole in the treatment of typhoid fever in children. Acta Paediatr. Jpn. 39: 218 221.
208. Segreti, J.,, T. D. Gootz,, L. J. Goodman,, G. W. Parkhurst,, J. P. Quinn,, B. A. Martin,, and G. M. Trenholme. 1992. Highlevel quinolone resistance in clinical isolates of Campylobacter jejuni. J. Infect. Dis. 165: 667 670.
209. Shapiro, R. L.,, L. Kumar,, P. Phillips-Howard,, J. G. Wells,, P. Adcock,, J. Brooks,, M. L. Ackers,, J. B. Ochieng,, E. Mintz,, S. Wahlquist,, P. Waiyaki,, and L. Slutsker. 2001. Antimicrobial-resistant bacterial diarrhea in rural western Kenya. J. Infect. Dis. 183: 1701 1704.
210. Shungu, D. L.,, E. Weinberg,, and H. H. Gadebusch. 1983. In vitro antibacterial activity of norfloxacin (MK-0366, AM- 715) and other agents against gastrointestinal tract pathogens. Antimicrob. Agents Chemother. 23: 86 90.
211. Sjogren, E.,, G. B. Lindblom,, and B. Kaijser. 1997. Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli isolates from Swedish patients. J. Antimicrob. Chemother. 40: 257 261.
212. Slutsker, L.,, A. A. Ries,, K. Maloney,, J. G. Wells,, K. D. Greene,, and P. M. Griffin. 1998. A nationwide case-control study of Escherichia coli 0157:H7 infection in the United States. J. Infect. Dis. 177: 962 966.
213. Smith, K. E.,, J. M. Besser,, C. W. Hedberg,, F. T. Leano,, J. B. Bender,, J. H. Wicklund,, B. P. Johnson,, K. A. Moore,, and M. T. Osterholm. 1999. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N. Engl. J. Med. 340: 1525 1532.
214. Smith, M. D.,, N. M. Duong,, N. T. Hoa,, J. Wain,, H. D. Ha,, T. S. Diep,, N. P. Day,, T. T. Hien,, and N. J. White. 1994. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob. Agents Chemother. 38: 1716 1720.
215. Steffen, R.,, R. Jori,, H. L. DuPont,, J. J. Mathewson,, and D. Sturchler. 1993. Efficacy and toxicity of fleroxacin in the treatment of travelers' diarrhea. Am. J. Med. 94: 182S 186S.
216. Stephens, I.,, and M. M. Levine. 2002. Management of typhoid fever in children. Pediatr. Infect. Dis. J. 21: 157 158.
217. Stock, I.,, B. Henrichfreise,, and B. Wiedemann. 2002. Natural antibiotic susceptibility and biochemical profiles of Yersinia enterocolitica-like strains: Y. bercovieri, Y. mollaretii, Y. aldovae and 'Y. ruckeri.' J. Med. Microbiol. 51: 56 69.
218. Stock, I.,, and B. Wiedemann. 2001. Natural antimicrobial susceptibilities of Plesiomonas shigelloides strains. J. Antimicrob. Chemother. 48: 803 811.
219. Stolk-Engelaar, V. M.,, J. F. Meis,, J. A. Mulder,, F. L. Loeffen,, and J. A. Hoogkamp-Korstanje. 1995. In-vitro antimicrobial susceptibility of Yersinia enterocolitica isolates from stools of patients in The Netherlands from 1982-1991. J. Antimicrob. Chemother. 36: 839 843.
220. Taylor, D. N.,, J. L. Sanchez,, W. Candler,, S. Thornton,, C. McQueen,, and P. Echeverria. 1991. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann. Intern. Med. 114: 731 734.
221. Taylor, S. J. 1997. Treating diarrhoea. Proposals are irresponsible and impractical. Br. Med. J . 315: 1377 1378.
222. Thomas, M. E.,, and N. Datta. 1969. Emergence of Shigella sonnei resistant to kanamycin and to nalidixic acid, without exposure to these drugs. J. Med. Microbiol. 2: 457 461.
223. Thomsen, L. L.,, and A. Paerregaard. 1998. Treatment with ciprofloxacin in children with typhoid fever. Scand. J. Infect. Dis. 30: 355 357.
224. Thornton, S. A.,, S. F. Wignall,, M. E. Kilpatrick,, A. L. Bourgeois,, C. Gardiner,, R. A. Batchelor,, D. H. Burr,, J. J. Oprandy,, P. Garst,, and K. C. Hyams. 1992. Norfloxacin compared to trimethoprim/sulfamethoxazole for the treatment of travelers' diarrhea among U.S. military personnel deployed to South America and West Africa. Mil. Med. 157: 55 5S.
225. Threlfall, E. J.,, A. Graham,, T. Cheasty,, L. R. Ward,, and B. Rowe. 1997. Resistance to ciprofloxacin in pathogenic Enterobacteriaceae in England and Wales in 1996. J. Clin. Pathol. 50: 1027 1028.
226. Threlfall, E. J.,, and L. R. Ward. 2001. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype typhi, United Kingdom. Emerg. Infect. Dis. 7: 448 450.
227. Threlfall, E. J.,, L. R. Ward,, J. A. Skinner,, H. R. Smith,, and S. Lacey. 1999. Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 353: 1590 1591.
228. Thwaites, R. T.,, and J. A. Frost. 1999. Drug resistance in Campylobacter jejuni, C coli, and C lari isolated from humans in north west England and Wales, 1997. J. Clin. Pathol. 52: 812 814.
229. Tran, T. H.,, D. B. Bethell,, T. T. Nguyen,, J. Wain,, S. D. To,, T. P. Le,, M. C. Bui,, M. D. Nguyen,, T. T. Pham,, A. L. Walsh, et al. 1995. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin. Infect. Dis. 20: 917 923.
230. Tran, T. H.,, M. D. Nguyen,, D. H. Huynh,, T. T. Nguyen,, S. D. To,, T. P. Le,, and K. Arnold. 1994. A randomized comparative study of fleroxacin and ceftriaxone in enteric fever. Trans. R. Soc. Trop. Med. Hyg. 88: 464 465.
231. Truong, Q. C, S. Ouabdesselam, D. C. Hooper, N. J. Moreau, and C. J. Soussy. 1995. Sequential mutations of gyrA in Escherichia coli associated with quinolone therapy. J. Antimicrob. Chemother. 36: 1055 1059.
232. Unal, S.,, M. Hayran,, S. Tuncer,, D. Gur,, O. Uzun,, M. Akova,, and H. E. Akalin. 1996. Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial. Antimicrob. Agents Chemother. 40: 2898 2900.
233. Usubutun, S.,, C. Agalar,, C. Diri,, and R. Turkyilmaz. 1997. Single dose ciprofloxacin in cholera. Eur. J. Emerg. Med. 4: 145 149.
234. Uwaydah, A. K.,, H. al Soub,, and I. Matar. 1992. Randomized prospective study comparing two dosage regimens of ciprofloxacin for the treatment of typhoid fever. J. Antimicrob. Chemother. 30: 707 711.
235. Van Looveren, M.,, G. Daube,, L. De Zutter,, J. M. Dumont,, C. Lammens,, M. Wijdooghe,, P. Vandamme,, M. Jouret,, M. Cornelis,, and H. Goossens. 2001. Antimicrobial susceptibilities of Campylobacter strains isolated from food animals in Belgium. J. Antimicrob. Chemother. 48: 235 240.
236. Vanhoof, R.,, J. M. Hubrechts,, E. Roebben,, H. J. Nyssen,, E. Nulens,, J. Leger,, and N. De Schepper. 1986. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms. Infection. 14: 294 298.
237. Velmonte, M. A.,, and C. S. Montalban. 1988. Norfloxacin in the treatment of infections caused by Salmonella typhi. Scand. J. Infect. Dis. Suppl. 56: 46 48.
238. Verdier, R. I.,, D. W. Fitzgerald,, W. D. Johnson, Jr.,, and J. W. Pape. 2000. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann. Intern. Med. 132: 885 888.
239. Vila, J.,, J. Gascon,, S. Abdalla,, J. Gomez,, F. Marco,, A. Moreno,, M. Corachan,, and T. Jimenez de Anta. 1994. Antimicrobial resistance of Shigella isolates causing traveler's diarrhea. Antimicrob. Agents Chemother. 38: 2668 2670.
240. Vila, J.,, M. Vargas,, C. Casals,, H. Urassa,, H. Mshinda,, D. Schellemberg,, and J. Gascon. 1999. Antimicrobial resistance of diarrheagenic Escherichia coli isolated from children under the age of 5 years from Ifakara, Tanzania. Antimicrob. Agents Chemother. 43: 3022 3024.
241. Vila, J.,, M. Vargas,, J. Ruiz,, M. Corachan,, M. T. Jimenez De Anta,, and J. Gascon. 2000. Quinolone resistance in enterotoxigenic Escherichia coli causing diarrhea in travelers to India in comparison with other geographical areas. Antimicrob. Agents Chemother. 44: 1731 1733.
242. Vila, J.,, M. Vargas,, J. Ruiz,, M. Espasa,, M. Pujol,, M. Corachan,, M. T. Jimenez de Anta,, and J. Gascon. 2001. Susceptibility patterns of enteroaggregative Escherichia coli associated with traveller's diarrhoea: emergence of quinolone resistance. J. Med. Microbiol. 50: 996 1000.